DDW 2024: Effect of Empagliflozin on Liver Fat in Metabolic-Dysfunction Associated Steatotic Liver Disease Patients without Diabetes Mellitus
Speaker presented research findings on a randomized control trial about the effects of empagliflozin on liver fat in non-diabetic patients. With no conflicts of interest to declare, the speaker highlighted that MARFL is highly prevalent, affecting about 32% globally. SGLT2 inhibitors have been shown to reduce liver fat in diabetic patients, but their effect on non-diabetic patients was unknown, prompting this trial. This investigator-initiated, double-blind, randomized placebo control trial was conducted at Queen Mary Hospital in Hong Kong. The hypothesis was that empagliflozin could reduce liver fat content in MASLD patients without diabetes. Inclusion criteria were adults aged 18 or older, randomly sampled from the community and screened for hepatic steatosis using transient elastography and MRI-derived proton density fat fraction (PDFF). Recruitment required an MRI PDFF of at least 5% and one MASLD criterion, excluding those with diabetes, excessive alcohol use, concurrent liver diseases, compensated cirrhosis, malignancy history, or severe renal impairments. The study design involved randomizing MASLD patients without diabetes into a 1:1 ratio to receive either empagliflozin 10 mg daily or placebo. Liver fat changes were measured using MRI PDFF at baseline and week 52.
The primary outcome was liver fat change difference between groups. Secondary outcomes included hepatic steatosis resolution. The trial was double-blind, placebo-controlled, at Queen Mary Hospital, Hong Kong. Speaker hypothesized empagliflozin could reduce liver fat in MASLD patients without diabetes. Inclusion criteria were adults over 18, screened for hepatic steatosis via MRI PDFF. Exclusions included diabetes, excessive alcohol use, liver diseases, cirrhosis, malignancy, and severe renal impairment. The study involved randomizing MASLD patients without diabetes to receive empagliflozin 10 mg daily or placebo, with liver fat measured at baseline and week 52. Sample size required 98 patients. Patient recruitment flow showed one lost to follow-up. Patient characteristics: average age 55, 55% male, BMI 27, mean MRI PDFF 9.6%. Intention-to-treat analysis showed a 2.5% drop in liver fat for the empagliflozin group, significant versus placebo. Subgroup analysis indicated effects mainly in patients over 60, females, and obese individuals. Secondary outcomes included nearly 50% hepatic steatosis resolution in the empagliflozin group versus 26% in placebo. Empagliflozin led to significant body weight reduction, BMI, and waist circumference decreases. Ferritin levels dropped significantly in the empagliflozin group, indicating reduced hepatic inflammation. ALT and AST drops showed borderline significance. Fasting glucose also dropped slightly in the empagliflozin group, but no significant differences were found for A1c and lipid profiles. Adverse events were similar between groups, with self-limiting urogenital symptoms. UTI cases were managed effectively, demonstrating empagliflozin's potential benefit in reducing liver fat in non-diabetic MASLD patients.
The speaker explained that the potential mechanisms for the study findings include weight loss effects and proposed effects such as mitigating inflammation and oxidative stress, enhancing beta-oxidation, and molecular pathway exports. However, the study has limitations due to the lack of liver biopsy, which is invasive. Nevertheless, significant improvements in ferritin levels were observed in the empagliflozin group, indicating potential histological severity prediction and fibrosis regression. Additionally, the findings may not be applicable to patients with severe hepatic steatosis or high liver transaminase levels. A lower dose of SGLT2 inhibitors was used compared to previous trials, which may affect the magnitude of the observed effects. Moreover, the results may not be generalizable to Western populations. In conclusion, empagliflozin use for 52 weeks significantly reduced liver fat content in MASLD patients without DM, along with improvements in serum ferritin levels, glucose, and anthropometric parameters, while maintaining a good safety profile.
Digestive Disease Week (DDW) 2024, May 18-21, 2024, Washington, D.C.



